Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis

What Was Tested

This registered not phased trial tested Desmopressin.

It had four arms (groups): Ginkgo Biloba group (experimental), Desmopressin group (active comparator), Combination group (experimental) and Placebo group (placebo comparator).

Patients in this group receive Ginkgo Biloba oral tablet.

Patients in this group receive Desmopressin oral tablets.

Patients in this group receive both Ginkgo Biloba and desmopressin oral tablets.

The registry classes the interventions as drug.

More on the Plan

Treatment is dominated by two approaches, enuresis alarm and drugs.

Treatment with drugs has largely been focused on tricyclic antidepressants especially imipramine or, more recently, antidiuretic agents such as desmopressin.

However, numerous reports of side effects, some lethal, have led to a decline in its use.

One of theory of nocturnal enuresis is deep sleep in children, this the main cornerstone in using Alarm as line of management.

Who Took Part

Enrollment: 398 actual participants took part.

It was open to people of any sex aged from 5 years up to 18 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: All children with monosymptomatic nocturnal enuresis.

The full record lists 1 inclusion and 1 exclusion criteria; among the exclusions: children with day and night wetting.

How the Study Was Run

It was run as a randomized, parallel-group and triple-blind study.

The participants were allocated by chance, so the Desmopressin group and the comparison group should start out alike.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Blinding on both sides kept the participants and researchers unaware of who received Desmopressin.

Those kept unaware of assignments: participant, investigator and outcomes assessor.

It started in 2024-11-01 with completion listed for 2025-12-01.

It ran at 1 site in Egypt.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Night wetting frequency (time frame: 1, 3 months).

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Desmopressin in 398 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Desmopressin compound page, all human trials.